Pyrrole-imidazole polyamide targeted to break fusion sites in TMPRSS2 and ERG gene fusion represses prostate tumor growth

Daisuke Obinata,1,2,9 Akiko Ito,1,9 Kyoko Fujiwara,1,9 Ken-Ichi Takayama,2,4 Daisaku Ashikari,1,2 Yasutaka Murata,1 Kenya Yamaguchi,1 Tomohiko Urano,2,4 Tetsuya Fujimura,5 Noboru Fukuda,6 Masayoshi Soma,3 Takayoshi Watanabe,7 Hiroki Nagase,7 Satoshi Inoue2,4,8 and Satoru Takahashi1

1Department of Urology, Nihon University School of Medicine, Tokyo; 2Department of Anti-Aging Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo; 3Division of General Medicine, Department of Medicine, Nihon University School of Medicine, Tokyo; 4Department of Geriatric Medicine, The University of Tokyo, Tokyo; 5Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo; 6Department of Advanced Medicine and Advanced Research Institute of Sciences and Humanities, Nihon University School of Medicine, Tokyo; 7Chiba Cancer Center Research Institute, Chiba; 8Division of Gene Regulation and Signal Transduction, Research Center for Genomic Medicine, Saitama Medical University, Saitama, Japan

Key words
Androgen receptor, fusion gene, prostate cancer, pyrrole–imidazole polyamide, TMPRSS2-ERG

Correspondence
Satoshi Inoue, Department of Anti-Aging Medicine, Graduate School of Medicine, University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
Tel: 81-3-5800-8834; Fax: +81-3-5800-9126; E-mail: INOUE-GER@h.u-tokyo.ac.jp

These authors contribute equally to this work.

Funding information
This work was supported by Grants of the Cell Innovation Program (to S. I.) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan; by the 2011–2015 Strategic Research Foundation for Private Universities (to M. S., D. O., K. F., N. F. and S. T.) from the MEXT-Supported Program; by Grants (to D. O., S. I., T. U. and S. T.) from Japan Society for the Promotion of Science, Japan; by the 2010 Research Grant of the 60th Anniversary Memorial Fund (to D. O.) from the Nihon University Medical Alumni Association; by the Young Researcher Promotion Grant (to D. O.) from The Japanese Urological Association; and by the Program for Promotion of Fundamental Studies in Health Sciences (S. I.), National Institute of Biomedical Innovation, Japan.

Received May 10, 2014; Revised July 18, 2014; Accepted July 23, 2014

Cancer Sci 105 (2014) 1272–1278

doi: 10.1111/cas.12493

Aberrant overexpression of ERG induced by the TMPRSS2-ERG gene fusion is likely involved in the development of prostate cancer. Synthetic pyrrole–imidazole (PI) polyamides recognize and attach to the minor groove of DNA with high affinity and specificity. In the present study, we designed a PI polyamide targeting TMPRSS2-ERG translocation breakpoints and assessed its effect on human prostate cancer cells. Our study identified that this PI polyamide repressed the cell and tumor growth of androgen-sensitive LNCaP prostate cancer cells. Targeting of these breakpoint sequences by PI polyamides could be a novel approach for the treatment of prostate cancer.

The androgen receptor (AR) plays a key role in the physiological development of the normal prostate epithelium as well as in the onset and progression of prostate cancer.1 AR is a member of the nuclear receptor superfamily and functions as a ligand-dependent transcription factor.2 Upon activation by androgens, AR translocates into the nucleus and binds to androgen responsive elements (ARE).

Recently, fusion of the prostate-specific androgen-regulated TMPRSS2 gene to the E26 transformation-specific (ETS) family transcription factor gene ERG was reported as a common event in prostate cancer.3–7 ETS family members modulate many cellular functions, including proliferation, apoptosis, differentiation, tissue remodeling, migration, invasion and angiogenesis.8–10 Altered expression or properties of ETS transcription regulators affect the control of these processes and are involved in carcinogenesis and cancer progression. Several studies have demonstrated that ETS family gene re-arrangements are linked to clinicopathological indicators in prostate cancer.11–13 Because TMPRSS2, 5′-fusion partners, are upregulated by androgen, AR has been supposed to be important to
regulate the fusion of genes in prostate cancer. A recent study shows that AR induces intronic binding sites in TMPRSS2 and ERG to facilitate specific chromosomal translocations by utilizing a common motif (TGT\ref{note1}AGGGA\ref{note2}T: break fusion site) for break ligation in the human prostate cancer cell line LNCaP, which does not harbor TMPRSS2-ERG endogenously.\cite{note1,note2,note3,note4}

Pyrrole–imidazole (PI) polyamides are small synthetic molecules that recognize and form non-covalent bonds to the minor groove of DNA, followed by inhibition of DNA–protein interactions with high affinity and sequence specificity.\cite{note5,note6,note7,note8} DNA recognition depends on a code of side-by-side pairing of pyrrole and imidazole in the hairpin polyamide, which binds to the minor groove. A pairing of imidazole opposite pyrrole targets for the G–C base pair, and pyrrole–pyrrole targets for both T–A and A–T base pairs. Recently, various types of sequence-specific PI polyamides have been developed to control gene expression.\cite{note9,note10,note11,note12,note13,note14} These investigations indicate that targeted PI polyamides could be potential gene silencers for the treatment of cancer. The aim of the present study is to investigate the effects of a PI polyamide targeting the TMPRSS2-ERG translocation break fusion site (fusion polyamide) in prostate cancer. We demonstrate that the fusion polyamide decreases the expression of TMPRSS2-ERG and ERG in LNCaP cells. In addition, we show that this polyamide represses the growth and migration of prostate cancer cells in vitro and in vivo.

Material and Methods

Cell culture, treatment with pyrrole–imidazole polyamide and antibody. The human prostate cancer cell lines LNCaP, VCaP and PC3 were purchased from the American Type Culture Collection (Rockville, MD, USA). LNCaP cells were maintained as previously described.\cite{note15} VCaP and PC3 cells were cultured in DMEM supplemented with 10% FBS. PI polyamides were synthesized at Nihon University (Tokyo, Japan), as previously described.\cite{note16} LNCaP cells were treated with negative control PI polyamide (negative control) and PI polyamide that targets break fusion sites (fusion polyamide) as previously described.\cite{note17} A rabbit polyclonal anti-cleaved caspase-3
antibody was purchased from Cell Signaling Technology (Danvers, MA, USA).

**DNA binding assay.** FITC-labeled oligonucleotides were synthesized for gel mobility shift assays as described below.

**TMPRSS2:** 5'-FITC-TGTTAAGCTAGGTTGTTGGAAGA TGTGTTTCACCTCTCCAACAACCTACGCTAAAACA-3'.

**ERG:** 5'-FITC-TCATGTTTTGGTGTTGTTGTTG-3'.

Both TMPRSS2 and ERG nucleotides contain the sequence TGT⁄AGGGA⁄T, which is the break fusion site in TMPRSS2 and ERG. Next, 1 µM of FITC-labeled oligonucleotides were dissolved in annealing buffer (20 mM Tris–HCl, 2 mM EDTA, 200 mM NaCl) and incubated at 100°C for 3 min. The solution was cooled down gradually to 30°C in the next 70 min to anneal the oligonucleotides in such a way that hairpin structures were formed. Then, 15 µL of annealed oligonucleotides and 5 µL of 2, 4 or 20 µM polyamides were mixed and incubated at 37°C for 1 h. The mixtures were separated by electrophoresis in 1× Tris-buffered EDTA on a 4–20% acrylamide gel and visualized with the luminescent image analyzer LAS-4000 (Fujifilm, Tokyo, Japan).

**FISH.** LNCaP cells were stimulated with vehicle or 100 nM dihydrotestosterone (DHT) in the presence of negative control or fusion polyamide for 24 h. Isolation of nuclear proteins and DNA-FISH were carried out according to methods previously described (Ourgenic, Tokushima, Japan). The probes were synthesized by Integrated DNA Technologies (Coralville, IA, USA) as listed below:

**ERG**
Biotin-GACTCCAGGAGCGCTCCCCAGAATCCCCTCC
TTAACCCAAACTCGAGCC.

**TMPRSS2**
FITC(FAM)-GATCTTTGGAGACCCGAGGAAAGCCGTG
TTGGACCAAAAGCAAGAATG.

**Quantitative RT-PCR.** Total RNA extraction, first-strand cDNA synthesis and quantitative RT-PCR (qRT-PCR) were performed as previously described. LNCaP cells were treated with 5 µM of negative control PI polyamide or 1 or 5 µM...
two days after treatment with DHT (100 nM), the mRNA expression levels of TMPRSS2-ERG and ERG were analyzed. As a negative control, cDNA samples prepared without reverse transcriptase were used. The primer sequences were as listed below.\(^{(11,25)}\)

\[
\begin{align*}
\text{ERG} \\
\text{Forward: } & 5'-\text{ACCGTTGGGATGAACCTACGGCA} - 3' \\
\text{Reverse: } & 5'-\text{TGGAGATGTGAGAGAAGGATGTCG} \\
\text{TMPRSS2-ERG} \\
\text{Forward: } & 5'-\text{AGCGCGGCAGGTTATTCCA} - 3' \\
\text{Reverse: } & 5'-\text{ATCATGTCTTCATGTAAGGCA} - 3'.
\end{align*}
\]

**Cell proliferation assay.** The cell growth rate was measured using an MTS proliferation assay (CellTiter 96 AQueous One Solution Cell Proliferation Assay; Promega, Madison, WI, USA), as previously described\(^{(26)}\) following the manufacturer’s instructions. Briefly, 5000 cells/well were seeded in 96-well plates and cultured in phenol red-free RPMI 1640 (LNCaP cells) or phenol red-free DMEM (PC3 and VCaP cells) medium supplemented with 2.5% charcoal-stripped FBS for 24, 48 and 96 h. Each condition was tested in quadruplicate wells and each experiment was repeated at least twice.

**Cell migration assay.** The cell migration assay was performed as previously described.\(^{(26)}\) Briefly, 50,000 cells were suspended in 30 \(\mu\)L of RPMI 1640 (LNCaP cells) or DMEM (PC3 and VCaP cells) medium containing 10% FBS and added to the upper chamber. After incubation for 24 h in LNCaP and PC3 cells or 48 h in VCaP cells at 37°C in a humid 5% \(\text{CO}_2\) atmosphere, the cells on the lower surface of the filter were fixed in methanol for 30 min, then stained with Giemsa solution (Muto Pure Chemicals, Tokyo, Japan) for 30 s. The cells on the lower surface were counted in at least five fields at a magnification of \(\times 200\) under a microscope.

**Analysis of the in vivo effects of polyamides.** Three million LNCaP cells were injected subcutaneously into each side of 7-week-old male nude mice (\(n = 12\)). When the tumor size reached 100 mm\(^3\), fusion polyamide or negative control polyamide (6 mg/kg body weight) dissolved in dH\(_2\)O were injected via the tail vein once a week for 4 weeks. The tumor size was measured every week until 1 week after the final injection, at which point the animals were killed and dissected. Tumor tissues were collected and kept both frozen and fixed in 10% formalin for analysis. Immunohistochemistry analysis was performed as previously described.\(^{(25)}\) The sections were incubated with the cleaved caspase-3 polyclonal antibody (1:100 dilution) overnight, followed by a 60-min incubation with Histofine Simple Stain MAX-PO (Nichirei, Tokyo, Japan).

**Statistical analysis.** Data are presented as mean ± SD or SEM. Statistical differences between the results of each group and its corresponding control were evaluated using Student’s \(t\)-test. A \(P\)-value of <0.05 was considered significant.

**Results**

**Binding of the polyamide to double-stranded DNA.** The fusion polyamide was designed to bind to the break fusion site in TMPRSS2 and ERG. As a control, negative control polyamide, which does not bind to these sites, was used (Fig. 1a,b). To determine the binding affinity and specificity of polyamide to target DNA, gel mobility shift assays were performed. Whereas oligonucleotides containing the break fusion site of TMPRSS or ERG showed mobility retardation when they were incubated with the fusion polyamide, nucleotides incubated with negative control polyamide did not show a clear mobility shift. The degree of mobility shift by the fusion polyamide was shown to be dose-dependent (Fig. 1c). The distribution of FITC-labeled fusion polyamide and negative control polyamide in LNCaP cells are shown in Fig. S1. After 2 h of incubation of LNCaP cells with 5 \(\mu\)M of FITC-labeled polyamide, strong fluorescent signals were detected in nuclei.

**Pyrrrole–imidazole polyamide targeting the break fusion site decreased fusion transcript and endogenous ERG.** Because previous reports show that TMPRSS2-ERG transcripts are induced in LNCaP cells by stimulation of DHT (100 nM) for 24 h,\(^{(11-14)}\) we analyzed LNCaP cells treated with the same protocol. To determine whether the fusion polyamide affects DHT-dependent inter-chromosomal movement and TMPRSS2-ERG expression in LNCaP cells, we performed FISH analysis and
measured TMPRSS2-ERG expression levels using qRT-PCR. After DHT treatment, the number of cells showing co-localization of TMPRSS2 and ERG was significantly increased in LNCaP cells cultured in the presence of 5 μM of negative control polyamide (Fig. 2). This DHT-induced inter-chromosomal movement, however, was significantly decreased in cells cultured with 5 μM of fusion polyamide. Although the TMPRSS2-ERG transcript was significantly and constantly expressed in VCaP cells, which harbor this fusion gene, its expression was induced to a detectable level by the stimulation with DHT in LNCaP cells. The expression of the TMPRSS2-ERG transcript was significantly suppressed in the presence of 5 μM of the fusion polyamide compared with 5 μM of negative control polyamide in LNCaP cells. In contrast, the fusion polyamide did not affect its expression in VCaP cells (Fig. 3a). Moreover, we tested whether the fusion polyamide could downregulate endogenous ERG gene expression. Both 1 and 5 μM of fusion polyamide substantially reduced mRNA expression levels of ERG in LNCaP cells (Fig. 3b).

**Fusion polyamide repressed cell growth and cell migration.** To assess the effect of the fusion polyamide on the viability of prostate cancer cells, we analyzed the cell proliferation activity by MTS assay. LNCaP cells treated with 1 and 5 μM fusion polyamide showed a significant decrease in cell proliferation after 96 h of DHT treatment compared to cells treated with negative control polyamide (P < 0.05; Fig. 4). The MTS assay also revealed that the fusion polyamide had no significant effect on cell proliferation in AR-negative and TMPRSS2-ERG-negative prostate cancer cell line PC3 cells and VCaP cells (Fig. 4). Next, we assessed the effects of the fusion polyamide on the migratory ability of LNCaP cells by conducting cell migration assays. Cell migration was significantly reduced in fusion polyamide-treated cells compared to negative control polyamide-treated cells (P < 0.0001; Fig. 5). Neither PC3 nor VCaP cells showed significant differences in average number of migratory cells between fusion polyamide-treated cells and negative control polyamide-treated cells (Fig. 5).

**Fusion polyamide repressed tumor growth in vivo.** Athymic male mice bearing LNCaP cell-derived tumors were treated with the fusion polyamide or negative control polyamide. Tumor growth was prominent in mice treated with the negative control polyamide, but it was substantially reduced in mice treated with the fusion polyamide (Fig. 6a,b). Moreover, the expression of cleaved caspase-3 tended to increase in LNCaP xenografts derived from mice treated with the fusion polyamide (Fig. 6c).

**Discussion**

Activation of AR signaling mediated by androgens promotes cancer progression. Several studies have shown that AR expression is positively correlated with standard clinical and pathologic parameters, including the Gleason grade, clinical stage, lymph node status, extracapsular extension and seminal vesicle invasion. The reports of the fusion of TMPRSS2 with ETS family members in prostate cancer have opened a new field in prostate cancer research. Approximately 80% of prostate tumors harbor genomic fusions of TMPRSS2 and members of the ETS family of transcription factors. Among them, approximately 50% contain TMPRSS2-ERG fusions. Recently, urine testing to detect TMPRSS2-ERG has been reported to demonstrate significant correlation of the expression level of this fusion transcript with Gleason score, clinical stage and extracapsular extension of the tumor. In addition, the expression of TMPRSS2-ERG promoted by AR has been associated with a poor clinical outcome. Those findings indicate that evaluation of the expression level of TMPRSS2-ERG is valuable not only for diagnosis but also for predicting prognosis. Furthermore, it is also indicated that repressing the mechanism of TMPRSS2-ERG expression is crucial for the development of therapeutic approaches. In the present study, we attempted to develop a new compound that can repress the fusion gene formation and/or expression and to assess its effect on prostate cancer growth.
A previous report showed that the expression of fusion transcripts was inhibited by siRNA, which target specific components involved in homologous recombination of DNA.\(^{(11)}\) Shao et al. (2012) report that siRNA targeting the most common isoforms of the TMPRSS2-ERG fusion transcript efficiently suppressed the growth of prostate cancer in vivo.\(^{(38)}\) Those data strongly suggest that inhibition of TMPRSS2-ERG fusion gene formation or expression could be a good therapeutic approach for prostate cancer. siRNA can effectively repress the expression of specific genes. However, there is a disadvantage in its application; that is, siRNA can be easily degraded by nucleases. One of the most important advantages of PI polyamide is that it is resistant to biological degradation (e.g. by nucleases and proteases). It can be taken up by cells and transported to nuclei without requiring any specific drug delivery system. Moreover, PI polyamide can inhibit DNA-protein interaction by binding to the minor groove of double-helical DNA with high affinity and sequence specificity.\(^{(15,16)}\) Another important advantage is that intravenous, subcutaneous or peritoneal injections of PI polyamide have never induced significant health injuries when tested in mice and rats.\(^{(18,19,39,40)}\) Raskatov et al.\(^{(41)}\) report that intra-peritoneal or subcutaneous administration of 120 nmol/mouse (4.5–7 mg/kg body weight) of PI polyamide in cyclic form had an acute toxic effect on mice; however, it was shown that the hairpin form of PI polyamide did not have any toxic effect at the same dose. In addition, Yang et al.\(^{(39)}\) report that subcutaneous injection of PI polyamides targeting RNA polymerase II resulted in growth reduction in LNCaP xenografts without detectable DNA damage. Therefore, in the present study, we designed and examined PI polyamide, which binds to break fusion sites, to inhibit double-stranded breaks. It has been reported previously that PI polyamide that recognizes ARE suppresses DHT-dependent gene expression in LNCaP cells,\(^{(42)}\) and it was revealed that this polyamide inhibits the binding of RNA polymerase II to the transcription start site of AR-driving genes.\(^{(39)}\)

Our present data clearly show that this fusion polyamide suppresses the formation and expression of TMPRSS2-ERG fusion genes. In addition, it suppressed endogenous ERG expression and cellular proliferation in in vitro models and also induced cellular apoptosis in in vivo models. Interestingly, the effect of PI polyamide on the inhibition of cell migration and in vivo tumor growth appeared to be drastic compared to its inhibitory effect on in vitro cell proliferation. Recent study has shown that the TMPRSS2-ERG fusion gene expressed in prostate cancer changes tumor microenvironment to that associated with more aggressive phenotype of cancer, and affects the cellular migration activity.\(^{(43-45)}\) For example, prostate cancer tissues with higher expression levels of TMPRSS2-ERG fusion transcripts showed increased vascular density, hyaluronan, von Willebrand factor and PDGFR\(\beta\), and decreased Caveolin-1. In addition, the in vivo tumor growth of prostate cancer cells is shown to be dependent on the microenvironment.\(^{(46,47)}\) These factors could explain the difference of the efficacy of the fusion polyamide between in vitro cell proliferation and in vivo tumor growth.

Endogenous ERG expression in prostate tissues was shown to be correlated with biochemical relapse and poor prognosis.\(^{(48,49)}\) Moreover, ERG overexpression in prostate cancer specimen is a strong predictor of the progression of the disease during active surveillance.\(^{(50)}\) Recently, it has been reported that the TMPRSS2–ERG fusion gene product binds to the ERG locus and promotes wild-type ERG expression in human prostate cancers.\(^{(51)}\) This mechanism activated the feed-forward regulation of ERG expression, thereby promoting prostate cancer invasion. This report also showed that the reduction of endogenous ERG expression prevented the invasion of prostate cancer cells. Furthermore, the report showed that overexpression of wild-type ERG was observed in 38% of clinically localized prostate cancers and 27% of metastatic prostate cancers bearing TMPRSS2-ERG fusion genes.\(^{(51)}\) These reports indicate that TMPRSS2-ERG plays a critical role in prostate cancer progression.

In summary, we developed a PI polyamide that can target the TMPRSS2-ERG fusion site, prevent formation of the fusion gene, and inhibit proliferation and migration of LNCaP cells as well as in vivo tumor growth. The present findings show that break fusion sites, which have a critical role in the formation of AR-dependent fusion genes, could be a novel therapeutic target for prostate cancer.

Acknowledgments
The authors thank Ms Asako Oguni, Ms Noriko Sasaki and Mr Motoaki Kataba for technical support and Ms Emiko Hododa for secretarial assistance.

Disclosure Statement
The authors have no conflict of interest to declare.

References
1 Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004; 25: 276–303.
2 Mantovani DJ, Thummel C, Beato M et al. The nuclear receptor superfamily: the second decade. Cell 1995; 83: 835–9.
3 Tomlins SA, Rhodes DR, Perner S et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644–8.
4 Tomlins SA, Mehra R, Rhodes DR et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 2006; 66: 3396–400.
5 Tomlins SA, Laxman B, Varambally S et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008; 10: 177–88.
6 Mehra R, Tomlins SA, Shen R et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 2007; 20: 538–44.
7 Mehra R, Tomlins SA, Yu J et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 2008; 68: 3584–90.
8 Okawa T, Yamada T. Molecular biology of the Ets family of transcription factors. Gene 2003; 303: 11–34.
9 Wang J, Cai Y, Ren C, Ittmann M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 2006; 66: 8347–51.
10 Perner S, Demichelis F, Beroukhim R et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006; 66: 8337–41.
11 Lin C, Yang L, Tanasa B et al. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 2009; 139: 1069–83.
12 Bastus NC, Boyd LK, Mao X et al. Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells. Cancer Res 2010; 70: 9544–8.
13 Haffner MC, Aryee MJ, Toubaei A et al. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet 2010; 42: 668–75.
14 Mami RS, Tomlins SA, Callahan K et al. Induced chromosomal proximity and gene fusions in prostate cancer. Science 2009; 326: 1230.
Nickols NG, Szabolowski JO, Hargrove AE, Li BC, Raskatov JA, Dervan PB. Activity of a py-im polyamide targeted to the estrogen response element. Mol Cancer Ther 2013; 12: 675–84.

Zhang Y, Sicot G, Cui X et al. Targeting a DNA binding motif of the ETV1 protein by a pyrrole-imidazole polyamide. Biochemistry 2011; 50: 10431–41.

Ueno T, Fukuda N, Tsunemi A et al. A novel gene silencer, pyrrole-imidazole polyamide targeting human lectin-like oxidized low-density lipoprotein receptor-1 gene improves endothelial cell function. J Hypertens 2009; 27: 508–16.

Takayama K, Kaneshiro K, Tsutsui S et al. Identification of novel androgen response genes in prostate cancer cells by coupling chromatin immunoprecipitation and genomic microarray analysis. Oncogene 2007; 26: 4453–63.

Hu Q, Kwon YS, Nunez E et al. Enhancing nuclear receptor-induced transcription requires nuclear motor and LSD1-dependent gene networking in interchromatin granules. Proc Natl Acad Sci USA 2008; 105: 19199–204.

Obinata D, Takayama K, Urano T et al. Oct1 regulates cell growth of LNCaP cells and is a prognostic factor for prostate cancer. Int J Cancer 2012; 130: 1021–8.

Obinata D, Takayama K, Urano T et al. ARF6GAP3, an androgen target gene, promotes prostate cancer cell proliferation and migration. Int J Cancer 2012; 130: 2240–8.

Lu S, Tsai SY, Tsai MJ. Regulation of androgen-dependent prostate cancer cell growth: androgen regulation of CDK2, CDK4, and CK1 p16 genes. Cancer Res 1997; 57: 4511–6.

Li R, Wheeler T, Dai H, Frolov A, Thompson T, Ayala G. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate cancer: patients treated with radical prostatectomy. Am J Surg Pathol 2004; 28: 928–34.

Clark JP, Cooper CS. ETS gene fusions in prostate cancer. Nat Rev Urol 2009; 6: 429–39.

Han B, Mehra R, Dhansakaran SM et al. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res 2008; 68: 7629–37.

Mehra R, Han B, Tomlins SA et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res 2007; 67: 7991–5.

King JC, Xu J, Wongvipat J et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 2009; 41: 524–6.

Carver BS, Tran J, Gopalani A et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 2009; 41: 619–24.

Laxman B, Tomlins SA, Mehra R et al. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 2006; 8: 885–8.

Leyten GH, Hessels D, Jannink SA et al. Prospective multicentre evaluation of PCA3 and TMPRSS2:ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol 2014; 65: 534–42.

Cerveira N, Ribeiro FR, Peixoto A et al. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPN lesions. Neoplasia 2006; 8: 826–32.

Demichelis F, Fall K, Perner S et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007; 26: 4596–9.

Shao L, Tekedeler I, Wang J et al. Highly specific targeting of the TMPRSS2:ERG fusion gene using liposomal nanovesicles. Clin Cancer Res 2012; 18: 6648–57.

Yang F, Nickols NG, Li BC, Marinov GK, Said JW, Dervan PB. Antitumor activity of a pyrrole-imidazole polyamide. Proc Natl Acad Sci USA 2013; 110: 1863–8.

Raskatov JA, Nickols NG, Hargrove AE, Marinov GK, Wold B, Dervan PB. Gene expression changes in a tumor xenograft by a pyrrole-imidazole polyamide. Proc Natl Acad Sci USA 2012; 109: 16041–5.

Raskatov JA, Hargrove AE, So AV, Dervan PB. Pharmacokinetics of Py-im polyamides depend on architecture: cyclic versus linear. J Am Chem Soc 2012; 134: 7995–9.

Nickols NG, Dervan PB. Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide. Proc Natl Acad Sci USA 2007; 104: 10418–23.

Hagglof C, Hammarsten P, Stromwall K et al. TMPRSS2:ERG expression predicts prostate cancer survival and associates with stromal biomarkers. PLoS ONE 2014; 9: e86824.

Selvaraj N, Budka JA, Ferris MW, Jerde TJ, Hollenhorst PC. Prostate cancer ETS rearrangements switch a cell migration gene expression program from RASSR to PI3K/AKT regulation. Mol Cancer 2014; 13: 61.

Tian YV, Tomavo N, Huot L et al. Identification of novel TMPRSS2:ERG mechanisms in prostate cancer metastasis: involvement of MMP9 and PLXNA2. Oncogene 2014; 33: 2204–14.

Halahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646–74.

Hagglof C, Bergh A. The stroma—a key regulator in prostate function and malignancy. Cancers 2012; 4: 531–48.

Warrick JI, Tomlins SA, Carskadon SL et al. Evaluation of tissue PCA3 expression in prostate cancer by RNA in situ hybridization—a correlative study with urine PCA3 and TMPRSS2-ERG. Mod Pathol 2014; 27: 689–90.

Huang KC, Dolph M, Donnelly B, Bismar TA. ERG expression is associated with increased risk of biochemical relapse following radical prostatectomy in early onset prostate cancer. Clin Transl Oncol. 2014; in press.

Berg KD, Vainer B, Thomsen FB et al. ERG protein expression in diagnostic specimens is associated with increased risk of progression during active surveillance for prostate cancer. Eur Urol 2014; in press.

Mani RS, Iyer MK, Cao Q et al. TMPRSS2:ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers. Cancer Res 2011; 71: 5387–92.